Tandem Diabetes Care Inc [TNDM] stock is trading at $11.93, up 7.96%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TNDM shares have gain 10.26% over the last week, with a monthly amount drifted -22.73%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Tandem Diabetes Care Inc [NASDAQ: TNDM] stock has seen the most recent analyst activity on August 12, 2025, when Citigroup upgraded its rating to a Neutral but kept the price target unchanged to $10.35 for it. Previously, Piper Sandler downgraded its rating to Neutral on August 07, 2025, and kept the price target unchanged to $14. On July 09, 2025, downgrade downgraded it’s rating to Sell but maintained its price target of $14 on the stock. Truist started tracking the stock assigning a Hold rating and suggested a price target of $24 on June 16, 2025. Mizuho initiated its recommendation with a Neutral and recommended $20 as its price target on April 10, 2025. Morgan Stanley downgraded its rating to Equal-Weight for this stock on March 05, 2025, and downed its price target to $22. In a note dated March 04, 2025, Citigroup downgraded a Neutral rating on this stock and revised its target price from $35 to $24.
Tandem Diabetes Care Inc [TNDM] stock has fluctuated between $9.98 and $47.60 over the past year. Currently, Wall Street analysts expect the stock to reach $27.6 within the next 12 months. Tandem Diabetes Care Inc [NASDAQ: TNDM] shares were valued at $11.93 at the most recent close of the market. An investor can expect a potential return of 131.35% based on the average TNDM price forecast.
Analyzing the TNDM fundamentals
Tandem Diabetes Care Inc [NASDAQ:TNDM] reported sales of 1.00B for the trailing twelve months, which represents a growth of 8.46%. Gross Profit Margin for this corporation currently stands at 0.47% with Operating Profit Margin at -0.18%, Pretax Profit Margin comes in at -0.18%, and Net Profit Margin reading is -0.18%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -1.04 and Total Capital is -0.32. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.37.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.37 points at the first support level, and at 10.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.29, and for the 2nd resistance point, it is at 12.64.
Ratios To Look Out For
For context, Tandem Diabetes Care Inc’s Current Ratio is 2.44. In addition, the Quick Ratio stands at 1.88 and the Cash Ratio stands at 0.25. Considering the valuation of this stock, the price to sales ratio is 0.80, the price to book ratio is 6.04.
Transactions by insiders
Recent insider trading involved Sheridan John F, PRESIDENT & CEO, that happened on Aug 11 ’25 when 10000.0 shares were purchased. EVP & CHIEF FINANCIAL OFFICER, Vosseller Leigh completed a deal on Aug 08 ’25 to buy 13720.0 shares. Meanwhile, EVP & Chief Operating Officer Kyrillos Jean-Claude bought 10538.0 shares on Mar 07 ’25.
